Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hopewell Therapeutics

Request full access

Synthetic Lipid for Gene Therapy and Genome Editing

Woburn, United StatesFounded 2018Biotech & Life Sciences

About Hopewell Therapeutics

Hopewell Therapeutics is a biotechnology firm concentrated on developing the next generation of genomic medicines through its proprietary tissue-targeted Lipid Nanoparticle (ttLNP) technology. The company was established in 2021, building upon a decade of research from Tufts University. It was scientifically founded by Dr. Qiaobing Xu, a Professor of Biomedical Engineering at Tufts University, who now serves as the company's Chief Technology Officer. Dr. Xu's extensive research forms the basis of Hopewell's intellectual property, which is exclusively licensed from the university. The company is led by President and CEO, Dr. Louis Brenner, an experienced biotech industry executive.

The core of Hopewell's business is its ttLNP platform, which is engineered to deliver a variety of genomic cargoes—such as mRNA, siRNA, DNA, and gene-editing tools—directly to specific tissues and cells outside of the liver (extrahepatic targets). This technology aims to overcome the delivery limitations of current LNP systems, potentially offering better targeting, biocompatibility, and sustained effects with repeat dosing. The firm's business model involves a dual approach: developing its own internal pipeline of therapies and forming strategic partnerships with other industry leaders to leverage its delivery platform. This strategy allows Hopewell to explore a wide range of applications for its technology. The company generates revenue through these partnerships and by advancing its own therapeutic products. The company has secured significant seed financing, raising a total of $32.1 million over two rounds, including a $25 million round in May 2023, to fund its operations, research, and development. Key investors include Mass Ave Capital, 5Y Capital, and HIKE Capital.

Hopewell's primary service is providing a sophisticated, non-viral delivery system for complex genomic medicines. This platform is designed to address unmet medical needs across several challenging disease areas. The initial focus of its internal pipeline is on pulmonary diseases, where preclinical studies have shown successful delivery of genetic material to key cell types in the lungs. Beyond lung diseases, the company is actively exploring applications for its ttLNP platform in oncology, infectious diseases, rare genetic disorders, and neurological conditions. Preclinical data presented at scientific conferences has demonstrated the platform's ability to systemically deliver cargoes to specific cellular targets in the lung, spleen, and liver, as well as targeting various immune cells for vaccine development.

Source: Dealroom company data

At a glance

Status
Operational
Employees
5
Open positions
1
Dealroom signal
40.9/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Jun 2023 $25M $100M Hike Capital · BOPU · Massachusetts Avenue Capital · WS Investments ↗
EARLY VC✓Equity / VC Feb 2022 $7.1M $28M Undisclosed ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Hopewell Therapeutics website traffic

Latest recorded traffic for Hopewell Therapeutics is 1.6K monthly website visits, up 175.9% over the last three months. Hopewell Therapeutics's team grew 66.7% over the past year.

Latest monthly visits1.6K 3-month web change+175.9% 1-year team growth+66.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Hopewell Therapeutics in the Woburn ecosystem

Live from Dealroom

The Hopewell Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed6 investors entered at this stage

  • Hike Capital
  • BOPU
  • Massachusetts Avenue Capital
  • WS Investments
  • IMO Ventures
  • 5Y Capital

Other known investors1 additional known investor

  • University of Alberta
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hopewell Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hopewell Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.